Ligand Pharmaceuticals Incorporated (LGND) Q4 2013 Earnings Results

Ligand Pharmaceuticals Beats on EPS, Stock Up 13.83%

Ligand Pharmaceuticals reported a strong earnings surprise, with EPS significantly exceeding expectations. The stock reacted positively, rising 13.83%, likely driven by investor confidence in the company's performance and future prospects. The lack of revenue data and guidance may leave some investors cautious, but the EPS beat suggests underlying strength in the business.

The print

Key numbers

Actual vs. consensus

Metric	Actual	Expected	Surprise
EPS	$0.35	N/A	+77.66%
Revenue	N/A	N/A	N/A

Management

Management commentary

Tone: Cautiously Optimistic

Overall, management conveyed a sense of optimism about the company's direction. However, they did not offer specific guidance for the upcoming quarters.

Management highlighted strong performance in their core business areas.

They expressed confidence in future growth despite not providing specific guidance.

Ligand Pharmaceuticals Beats on EPS, Stock Up 13.83%

Key numbers

Management commentary

Ligand Pharmaceuticals Incorporated

More earnings this week

Ligand Pharmaceuticals Beats on EPS, Stock Up 13.83%

Key numbers

Management commentary